Trial Profile
Randomised phase IIa trial of CYT 003 QbG10 with or without grass pollen extract versus placebo in patients with mild to moderate seasonal allergic rhinitis due to grass pollen allergy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2007
Price :
$35
*
At a glance
- Drugs Vidutolimod (Primary)
- Indications Hypersensitivity; Seasonal allergic rhinitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cytos Biotechnology
- 14 Mar 2007 Interim results have been reported
- 14 Mar 2007 Status changed from initiated to completed
- 14 Jun 2006 New trial record.